Name | (±)-Lisofylline |
---|---|
Synonyms |
R-1-(5-Hydroxyhexyl)-3,7-dimethylxanthine
(R)-3,7-Dihydro-1-(5-hydroxyhexyl)-3,7-dimethyl-1H-purine-2,6-dione 1-[(5R)-5-Hydroxyhexyl]-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione Penthydroxifillyne HYDROXY PENTOXIFYLLINE Lisofylline 1-(5-Hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione 1H-Purine-2,6-dione, 3,7-dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl- UNII:R99EE080JS 1H-Purine-2,6-dione, 3,7-dihydro-1-(5-hydroxyhexyl)-3,7-dimethyl- ProTec 1H-Purine-2,6-dione, 3,7-dihydro-1-(5-hydroxyhexyl)-3,7-dimethyl-, (R)- 1-[(R)-5-Hydroxyhexyl]theobromine CT 1501R |
Description | (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research[1]. |
---|---|
Related Catalog | |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 511.2±56.0 °C at 760 mmHg |
Melting Point | 123-125ºC |
Molecular Formula | C13H20N4O3 |
Molecular Weight | 280.323 |
Flash Point | 263.0±31.8 °C |
Exact Mass | 280.153534 |
PSA | 82.05000 |
LogP | 0.34 |
Appearance | solid | white |
Vapour Pressure | 0.0±1.4 mmHg at 25°C |
Index of Refraction | 1.621 |
Storage condition | Refrigerator |
Water Solubility | DMSO: soluble |
RIDADR | NONH for all modes of transport |
---|---|
WGK Germany | 3 |
~91% 6493-06-7 |
Literature: Kala, Elzbieta P.; Wojcik, Tomasz Acta Poloniae Pharmaceutica - Drug Research, 2007 , vol. 64, # 2 p. 109 - 113 |
Precursor 1 | |
---|---|
DownStream 0 |